Traws Pharma, Inc. (TRAW) - 10-K Summary
Business Context and Reporting Period
Company: Traws Pharma, Inc.
Filing Type: Form 10-K (Annual Report)
Period Covered: Fiscal year ended December 31, 2025
Business Overview: Traws is a clinical-stage biopharmaceutical company focused on respiratory viral diseases and oncology. Following a merger with Trawsfynydd Therapeutics, Inc. in April 2024, the company's portfolio includes four clinical programs: tivoxavir marboxil (influenza/bird flu), ratutrelvir (COVID-19), narazaciclib (oncology), and rigosertib (oncology/rare disease). The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $2.79 million | $0.23 million |
| Net Income (Loss) | $9.17 million | $(166.52) million |
| Operating Expenses | $20.67 million | $142.60 million |
| Research & Development | $12.14 million | $12.85 million |
| Cash and Cash Equivalents (Year-End) | $3.82 million | $21.34 million |
| Accumulated Deficit | $(639.98) million | $(649.15) million |
| Working Capital | $(3.17) million | $13.42 million |
Note: 2025 Net Income was driven primarily by a $26.57 million non-cash gain from the change in fair value of warrant liabilities. 2024 results included a $117.46 million non-cash charge for acquired in-process research and development (IPR&D) and a $24.44 million warrant expense.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased to $2.79 million from $0.23 million, primarily due to the immediate recognition of $2.73 million in deferred revenue following the termination of the license agreement with SymBio Pharmaceuticals Limited in April 2025.
- Expense Reduction: Total operating expenses decreased significantly to $20.67 million from $142.60 million. This reduction is largely attributable to the absence of the $117.5 million IPR&D charge recorded in 2024 related to the Trawsfynydd merger.
- Warrant Liability Gain: The company recorded a $26.57 million gain in 2025 due to the reclassification of warrant liabilities to equity and changes in fair value, contrasting with a $24.44 million expense in 2024.
- Cash Burn: Cash and cash equivalents declined by approximately $17.5 million during 2025, resulting in a year-end balance of $3.82 million.
Guidance, Outlook, Risks, and Unusual Items
Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. As of December 31, 2025, cash balances were insufficient to fund operations for the next 12 months. The independent auditor included an explanatory paragraph regarding this uncertainty in the audit report.
Recent Financing (Subsequent Event): On April 15, 2026, the company completed a financing transaction with gross proceeds of up to $60.0 million. This included $10.0 million in upfront cash and milestone-based warrants with potential aggregate exercise prices of $50.0 million. Despite this, management stated that even with these proceeds, substantial doubt regarding the going concern status remains for the 12-month period following the report date.
Regulatory Developments:
- Tivoxavir Marboxil: The FDA placed the U.S. IND on clinical hold in early 2026 due to concerns with the toxicology data package. The company is working to resolve this hold.
- Ratutrelvir: Completed enrollment in a Phase 2 study versus PAXLOVID. Interim data showed faster symptom resolution and no viral rebounds compared to the comparator.
Risks: Key risks include the need for additional financing, the clinical hold on tivoxavir marboxil, the uncertainty of clinical trial outcomes, and the potential for dilution from future equity offerings.
Investor Verification Checklist
- Liquidity Status: Verify the actual cash proceeds received from the April 2026 financing and the company's updated runway projections.
- FDA Clinical Hold: Monitor the status of the clinical hold on the tivoxavir marboxil U.S. IND and the timeline for resolution.
- Warrant Liability: Review the terms of the milestone-based warrants issued in the April 2026 financing to understand potential future dilution and cash inflow scenarios.
- Going Concern Opinion: Confirm if the company has secured sufficient non-dilutive funding to remove the "substantial doubt" qualification in future filings.
- Revenue Sustainability: Note that the 2025 revenue spike was a one-time event from contract termination; verify if any recurring revenue streams exist.